IVD in Singapore and Malaysia

IVD in Singapore and Malaysia

Regional opportunities are the focus of IVD manufacturers that seek marginal growth. Southeast Asia represents a unique market for healthcare providers and their various business suppliers, including the in vitro diagnostics (IVD) industry. Kalorama details in this report two countries expected to provide business for IVD manufacturers: Singapore and Malaysia.

IVD in Singapore and Malaysia contains the following information:

• Healthcare Statistics for Singapore and Malaysia
• Significant Hospitals in both countries
• The Clinical Lab Market in both Singapore and Malaysia
• Markets for Key Segments: Clinical Chemistry, Microbiology - Molecular, Microbiology - ID/AST, Point of Care - OTC Diabetes, Point of Care - Professional, Point of Care - OTC Other, Immunoassays - Infectious Disease, Immunoassays - Other, Urinalysis, Molecular Diagnostics, Histology, Coagulation, Blood Testing and Typing, Hematology, Flow Cytometry

Multinational competitors participate in the marketplaces of Singapore and Malaysia. Company portraits include the following:

• Abbott Laboratories (Singapore) Pte Ltd
• Beckman Coulter Singapore Pte Ltd
• Becton Dickinson Medical (Singapore) Pte Ltd
• Bio-Rad Laboratories (Singapore) Pte Ltd
• bioMérieux Singapore Pte Ltd
• Life Technologies Holdings Pte Ltd
• Roche Diagnostics Asia Pacific Pte Ltd
• Siemens Healthcare Diagnostics Pte Ltd
• Sysmex Asia Pacific Pte Ltd

Singapore is a leading port and center for the entire Asian-Pacific region, connecting regional trade. Featuring the most developed and highest rated healthcare system in Southeast Asia, Singapore is the headquarters and regional manufacturing center for several medical device, biotechnology, IVD, and pharmaceutical firms. Malaysia, its neighbor, is an upper middle-income country having perhaps the second-most developed healthcare system in the region of Southeast Asia. Through Singapore or Kuala Lumpur, IVD competitors have access to approximately 35 million potential patients, over 700,000 medical tourists yearly, and healthcare systems with higher per capita expenditures than anywhere else in Southeast Asia – or for that matter anywhere in Asia outside of Japan, Australia, or Korea. Singapore and Malaysia represent IVD industries and potential opportunities with solid fundamentals in clinical demand and strong prospects.